Sean Thomas Pianka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sean Thomas Pianka has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Albert Lai
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles , Los Angeles, CA
32 shared publications - Blaine S. C. Eldred
UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles
32 shared publications - Linda M. Liau
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, California, Los Angeles, CA, USA
32 shared publications - Phioanh Leia Nghiemphu
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
32 shared publications - Serendipity Zapanta Rinonos
Department of Neurosurgery, University of Florida, College of Medicine, Gainesville, Florida
32 shared publications - Terry J. Prins
Department of Neurology, UCLA Medical Center, Los Angeles, California
32 shared publications
Latest Publications
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
FTO inhibition attenuates gliomasphere growth. A, Increase in U87 RNA m6A content relative to control (0 µmol/L) following the application of FTO inhibitors FB23-2 (left) or MA (right) at various doses. Dose-dependent inhibition of U87 cell viability by FTO inhibitors FB23-2 (B) and MA (C) evaluated by MTT assay. D, Time course of m6A enrichment in U87 cells treated with the FTO inhibitor FB23-2 (3 µmol/L, red) or DMSO (blue). One representative dot blot comparison between FB23-2–treated or DMSO-treated U87 cells is shown below the graph. Growth inhibition following FTO inhibitor treatment (FB23-2 = 3 µmol/L; MA = 100 µmol/L) in IDH1wt HK217 (E) and HK250 (F) gliomaspheres. G, Treatment of both vector control and IDH1mut forced expressing U87 cells with MA results in decreased viability (ANOVA, F(3,16) = 271.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparisons at each dose between IDH1mut and vector). H, Treatment of HK385 gliomaspheres with the FTO inhibitor FB23-2 (3 µmol/L) attenuates sphere growth in vector gliomaspheres but not those exhibiting IDH1mut forced expression [ANOVA, treatment: F(1,937) = 51.1, P ≤ 0.0001; vector vs. IDH1mut: F(1,937) = 29.4, P ≤ 0.0001; interaction: F(1,937) = 31.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by horizontal bars]. I, IDH1mut inhibitor (C35 = 2 µmol/L; or AG881 = 1 µmol/L) treatment enhanced growth in IDH1mut forced expression HK252 gliomaspheres, thereby restoring sensitivity to FB23-2 (3 µmol/L) [ANOVA, IDHmut inhibitor treatment: F(2,1133) = 10.9, P ≤ 0.0001; FTO inhibitor treatment: F(1,1133) = 73.7, P ≤ 0.0001; interaction: F(2,1133) = 9.5, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by the horizontal bars]. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control or between two groups as indicated by the horizontal line.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
FTO inhibition attenuates gliomasphere growth. A, Increase in U87 RNA m6A content relative to control (0 µmol/L) following the application of FTO inhibitors FB23-2 (left) or MA (right) at various doses. Dose-dependent inhibition of U87 cell viability by FTO inhibitors FB23-2 (B) and MA (C) evaluated by MTT assay. D, Time course of m6A enrichment in U87 cells treated with the FTO inhibitor FB23-2 (3 µmol/L, red) or DMSO (blue). One representative dot blot comparison between FB23-2–treated or DMSO-treated U87 cells is shown below the graph. Growth inhibition following FTO inhibitor treatment (FB23-2 = 3 µmol/L; MA = 100 µmol/L) in IDH1wt HK217 (E) and HK250 (F) gliomaspheres. G, Treatment of both vector control and IDH1mut forced expressing U87 cells with MA results in decreased viability (ANOVA, F(3,16) = 271.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparisons at each dose between IDH1mut and vector). H, Treatment of HK385 gliomaspheres with the FTO inhibitor FB23-2 (3 µmol/L) attenuates sphere growth in vector gliomaspheres but not those exhibiting IDH1mut forced expression [ANOVA, treatment: F(1,937) = 51.1, P ≤ 0.0001; vector vs. IDH1mut: F(1,937) = 29.4, P ≤ 0.0001; interaction: F(1,937) = 31.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by horizontal bars]. I, IDH1mut inhibitor (C35 = 2 µmol/L; or AG881 = 1 µmol/L) treatment enhanced growth in IDH1mut forced expression HK252 gliomaspheres, thereby restoring sensitivity to FB23-2 (3 µmol/L) [ANOVA, IDHmut inhibitor treatment: F(2,1133) = 10.9, P ≤ 0.0001; FTO inhibitor treatment: F(1,1133) = 73.7, P ≤ 0.0001; interaction: F(2,1133) = 9.5, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by the horizontal bars]. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control or between two groups as indicated by the horizontal line.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Glioma Patient Sample Characteristics
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Glioma Patient Sample Characteristics
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Patient Derived Glioma Stem Cell Characteristics
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Patient Derived Glioma Stem Cell Characteristics
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Effects of Octyl-D-2-HG and IDH1mut Inhibitors on Glioma Cell Growth.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Effects of Octyl-D-2-HG and IDH1mut Inhibitors on Glioma Cell Growth.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
ATF5 is a Downstream Effector of the IDH1mut → D-2-HG ⊣ FTO Axis Resulting in Gliomasphere Growth Reduction.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
ATF5 is a Downstream Effector of the IDH1mut → D-2-HG ⊣ FTO Axis Resulting in Gliomasphere Growth Reduction.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 5 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Pharmacologic inhibition of FTO using FB23-2 reduces tumor growth rates in intracranial IDH1wt gliomasphere xenografts. A, Pharmacokinetic analysis of FB23-2 permeability through the BBB showing drug elimination dynamics in plasma and brain (2 mice/timepoint). B, Schematic of in vivo experiments whereby intracranial gliomasphere xenografts were established before undergoing randomization to daily intraperitoneal injections of either FB23-2 treatment or DMSO control, with injection volumes based on individual weights (20 mg/kg). In vivo monitoring of tumor growth measured via plasma Gaussia Luciferase activity (tail vein) revealed differences at 7–8 weeks (GS187) and 6–7 weeks (XDS4130; at week 8, only 1 mouse remained in DMSO group), respectively [ANOVA, (C) treatment: F(1,16) = 4.7, P ≤ 0.05; time: F(7,106) = 79.1, P ≤ 0.0001; interaction: F(7,106) = 4.3, P ≤ 0.0003; (D) treatment: F(1,18) = 16.7, P ≤ 0.0007; time: F(1.6,23.6) = 41.7, P ≤ 0.0001; interaction: F(7,104) = 5.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls on day 7 and 8]. Kaplan–Meier curves showing overall survival differences in xenograft mice treated with FB23-2 (3 µmol/L) or DMSO control, evaluated via a log-rank (Mantel–Cox) test for GS187 (E, P < 0.005) and XDS4130 (F, P ≤ 0.05). G, Activated Cas3 immunostaining (G, 10X magnification) of representative XDS4130 xenografts (surgically extracted and flash-frozen post-mortem). “MS” refers to the mouse identification number. H, Increase in number of Cas3 positive cells in tumors from mice treated with FB23-2 relative to DMSO controls (P ≤ 0.005). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 5 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Pharmacologic inhibition of FTO using FB23-2 reduces tumor growth rates in intracranial IDH1wt gliomasphere xenografts. A, Pharmacokinetic analysis of FB23-2 permeability through the BBB showing drug elimination dynamics in plasma and brain (2 mice/timepoint). B, Schematic of in vivo experiments whereby intracranial gliomasphere xenografts were established before undergoing randomization to daily intraperitoneal injections of either FB23-2 treatment or DMSO control, with injection volumes based on individual weights (20 mg/kg). In vivo monitoring of tumor growth measured via plasma Gaussia Luciferase activity (tail vein) revealed differences at 7–8 weeks (GS187) and 6–7 weeks (XDS4130; at week 8, only 1 mouse remained in DMSO group), respectively [ANOVA, (C) treatment: F(1,16) = 4.7, P ≤ 0.05; time: F(7,106) = 79.1, P ≤ 0.0001; interaction: F(7,106) = 4.3, P ≤ 0.0003; (D) treatment: F(1,18) = 16.7, P ≤ 0.0007; time: F(1.6,23.6) = 41.7, P ≤ 0.0001; interaction: F(7,104) = 5.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls on day 7 and 8]. Kaplan–Meier curves showing overall survival differences in xenograft mice treated with FB23-2 (3 µmol/L) or DMSO control, evaluated via a log-rank (Mantel–Cox) test for GS187 (E, P < 0.005) and XDS4130 (F, P ≤ 0.05). G, Activated Cas3 immunostaining (G, 10X magnification) of representative XDS4130 xenografts (surgically extracted and flash-frozen post-mortem). “MS” refers to the mouse identification number. H, Increase in number of Cas3 positive cells in tumors from mice treated with FB23-2 relative to DMSO controls (P ≤ 0.005). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Glioma Patient Sample Characteristics
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Glioma Patient Sample Characteristics
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 4 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
FTO inhibition attenuates gliomasphere growth. A, Increase in U87 RNA m6A content relative to control (0 µmol/L) following the application of FTO inhibitors FB23-2 (left) or MA (right) at various doses. Dose-dependent inhibition of U87 cell viability by FTO inhibitors FB23-2 (B) and MA (C) evaluated by MTT assay. D, Time course of m6A enrichment in U87 cells treated with the FTO inhibitor FB23-2 (3 µmol/L, red) or DMSO (blue). One representative dot blot comparison between FB23-2–treated or DMSO-treated U87 cells is shown below the graph. Growth inhibition following FTO inhibitor treatment (FB23-2 = 3 µmol/L; MA = 100 µmol/L) in IDH1wt HK217 (E) and HK250 (F) gliomaspheres. G, Treatment of both vector control and IDH1mut forced expressing U87 cells with MA results in decreased viability (ANOVA, F(3,16) = 271.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparisons at each dose between IDH1mut and vector). H, Treatment of HK385 gliomaspheres with the FTO inhibitor FB23-2 (3 µmol/L) attenuates sphere growth in vector gliomaspheres but not those exhibiting IDH1mut forced expression [ANOVA, treatment: F(1,937) = 51.1, P ≤ 0.0001; vector vs. IDH1mut: F(1,937) = 29.4, P ≤ 0.0001; interaction: F(1,937) = 31.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by horizontal bars]. I, IDH1mut inhibitor (C35 = 2 µmol/L; or AG881 = 1 µmol/L) treatment enhanced growth in IDH1mut forced expression HK252 gliomaspheres, thereby restoring sensitivity to FB23-2 (3 µmol/L) [ANOVA, IDHmut inhibitor treatment: F(2,1133) = 10.9, P ≤ 0.0001; FTO inhibitor treatment: F(1,1133) = 73.7, P ≤ 0.0001; interaction: F(2,1133) = 9.5, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by the horizontal bars]. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control or between two groups as indicated by the horizontal line.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 4 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
FTO inhibition attenuates gliomasphere growth. A, Increase in U87 RNA m6A content relative to control (0 µmol/L) following the application of FTO inhibitors FB23-2 (left) or MA (right) at various doses. Dose-dependent inhibition of U87 cell viability by FTO inhibitors FB23-2 (B) and MA (C) evaluated by MTT assay. D, Time course of m6A enrichment in U87 cells treated with the FTO inhibitor FB23-2 (3 µmol/L, red) or DMSO (blue). One representative dot blot comparison between FB23-2–treated or DMSO-treated U87 cells is shown below the graph. Growth inhibition following FTO inhibitor treatment (FB23-2 = 3 µmol/L; MA = 100 µmol/L) in IDH1wt HK217 (E) and HK250 (F) gliomaspheres. G, Treatment of both vector control and IDH1mut forced expressing U87 cells with MA results in decreased viability (ANOVA, F(3,16) = 271.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparisons at each dose between IDH1mut and vector). H, Treatment of HK385 gliomaspheres with the FTO inhibitor FB23-2 (3 µmol/L) attenuates sphere growth in vector gliomaspheres but not those exhibiting IDH1mut forced expression [ANOVA, treatment: F(1,937) = 51.1, P ≤ 0.0001; vector vs. IDH1mut: F(1,937) = 29.4, P ≤ 0.0001; interaction: F(1,937) = 31.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by horizontal bars]. I, IDH1mut inhibitor (C35 = 2 µmol/L; or AG881 = 1 µmol/L) treatment enhanced growth in IDH1mut forced expression HK252 gliomaspheres, thereby restoring sensitivity to FB23-2 (3 µmol/L) [ANOVA, IDHmut inhibitor treatment: F(2,1133) = 10.9, P ≤ 0.0001; FTO inhibitor treatment: F(1,1133) = 73.7, P ≤ 0.0001; interaction: F(2,1133) = 9.5, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with DMSO or between groups as indicated by the horizontal bars]. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control or between two groups as indicated by the horizontal line.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
IDH1mut production of D-2-HG inhibits gliomasphere growth. IDH1mut inhibitors (C35 = 2 µmol/L; AG881 = 1 µmol/L) enhance growth of IDH1mutpatient-derived gliomaspheres HK252 (A) and HK211 (B). C, Effect of IDH1mut forced expression in IDH1wt gliomaspheres (HK385, HK217, and HK250) on gliomasphere growth relative to vector control [ANOVA, F(1,1056) = 199.0, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector], showing decreased overall growth in IDH1mut. D, Octyl-D-2-HG (0.5 mmol/L) and FTO inhibitor MA (100 µmol/L) treatment inhibited growth of IDH1wt gliomaspheres (HK217 and HK250) [ANOVA, F(2,996) = 80.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison of octyl-D-2-HG or MA with PBS treatment]. Top: IDH1mut inhibitor (C35 = 2 µmol/L, or AG881 = 1 µmol/L) treatment reduces intracellular D-2-HG content (n = 1) in IDH1wt gliomaspheres [HK385 (E), HK217 (F), HK250 (G)] with IDH1mut forced expression. D-2-HG levels in untreated vector gliomaspheres were below detection threshold and were not visible. Bottom: IDH1wt gliomaspheres with IDH1mut forced expression exhibited differences in gliomasphere growth [ANOVA, E: F(1,353) = 9.6, P ≤ 0.002, F: F(1,890) = 30.6, P ≤ 0.0001, G: F(1,833) = 73.0, P ≤ 0.0001], and gliomasphere growth. IDH1mut forced expression spheres could be enhanced with IDH1mut inhibitor treatment [ANOVA, E: F(2,353) = 1.3, P ≤ 0.3, F: F(1,890) = 13.1, P ≤ 0.0003, G: F(1,833) = 14.8, P ≤ 0.0001]. Asterisks indicate post hoc Newman–Keuls comparisons between IDH1mut and vector, or between groups indicated by the horizontal bars. H, Treatment with octyl-D-2-HG (1.0 mmol/L) or FTO inhibitors (FB23–2 = 3 µmol/L; MA = 100 µmol/L) appeared to induce apoptosis (green fluorescence), but not necrosis (red fluorescence), in U87 cells using an Abcam Apoptosis/Necrosis Assay Kit (10X magnification). Quantification of increased apoptotic Caspase 3/7 activity (detected with Promega Caspase-Glo 3/7 Assay kit) in IDH1wt (I, J) and hemizygous IDH1mut/− BT142 (K) gliomaspheres following treatment with octyl-D-2-HG (0.5 mmol/L) or FTO inhibitor (FB23–2 = 3 µmol/L; MA = 100 µmol/L). L, Octyl-D-2-HG (0.5 mmol/L) or FTO inhibitor (FB23–2 = 3 µmol/L) treatment reduced PCNA expression in Western blots of IDH1wt gliomaspheres. M,IDH1wt gliomaspheres (HK217 and HK250) exhibiting IDH1mut forced expression demonstrated reduced PCNA expression via Western blot analysis. Treatment with IDH1mut inhibitor (AG881 = 1 µmol/L) was able to restore PCNA expression in IDH1mutgliomaspheres, but not in vector controls. N, IDH1mut inhibitor (AG881 = 1 µmol/L) treatment enhanced PCNA expression in native IDH1mut patient-derived gliomaspheres (HK211, HK252). PCNA protein expression was determined relative to GAPDH protein loading controls. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
IDH1mut production of D-2-HG inhibits gliomasphere growth. IDH1mut inhibitors (C35 = 2 µmol/L; AG881 = 1 µmol/L) enhance growth of IDH1mutpatient-derived gliomaspheres HK252 (A) and HK211 (B). C, Effect of IDH1mut forced expression in IDH1wt gliomaspheres (HK385, HK217, and HK250) on gliomasphere growth relative to vector control [ANOVA, F(1,1056) = 199.0, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector], showing decreased overall growth in IDH1mut. D, Octyl-D-2-HG (0.5 mmol/L) and FTO inhibitor MA (100 µmol/L) treatment inhibited growth of IDH1wt gliomaspheres (HK217 and HK250) [ANOVA, F(2,996) = 80.4, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison of octyl-D-2-HG or MA with PBS treatment]. Top: IDH1mut inhibitor (C35 = 2 µmol/L, or AG881 = 1 µmol/L) treatment reduces intracellular D-2-HG content (n = 1) in IDH1wt gliomaspheres [HK385 (E), HK217 (F), HK250 (G)] with IDH1mut forced expression. D-2-HG levels in untreated vector gliomaspheres were below detection threshold and were not visible. Bottom: IDH1wt gliomaspheres with IDH1mut forced expression exhibited differences in gliomasphere growth [ANOVA, E: F(1,353) = 9.6, P ≤ 0.002, F: F(1,890) = 30.6, P ≤ 0.0001, G: F(1,833) = 73.0, P ≤ 0.0001], and gliomasphere growth. IDH1mut forced expression spheres could be enhanced with IDH1mut inhibitor treatment [ANOVA, E: F(2,353) = 1.3, P ≤ 0.3, F: F(1,890) = 13.1, P ≤ 0.0003, G: F(1,833) = 14.8, P ≤ 0.0001]. Asterisks indicate post hoc Newman–Keuls comparisons between IDH1mut and vector, or between groups indicated by the horizontal bars. H, Treatment with octyl-D-2-HG (1.0 mmol/L) or FTO inhibitors (FB23–2 = 3 µmol/L; MA = 100 µmol/L) appeared to induce apoptosis (green fluorescence), but not necrosis (red fluorescence), in U87 cells using an Abcam Apoptosis/Necrosis Assay Kit (10X magnification). Quantification of increased apoptotic Caspase 3/7 activity (detected with Promega Caspase-Glo 3/7 Assay kit) in IDH1wt (I, J) and hemizygous IDH1mut/− BT142 (K) gliomaspheres following treatment with octyl-D-2-HG (0.5 mmol/L) or FTO inhibitor (FB23–2 = 3 µmol/L; MA = 100 µmol/L). L, Octyl-D-2-HG (0.5 mmol/L) or FTO inhibitor (FB23–2 = 3 µmol/L) treatment reduced PCNA expression in Western blots of IDH1wt gliomaspheres. M,IDH1wt gliomaspheres (HK217 and HK250) exhibiting IDH1mut forced expression demonstrated reduced PCNA expression via Western blot analysis. Treatment with IDH1mut inhibitor (AG881 = 1 µmol/L) was able to restore PCNA expression in IDH1mutgliomaspheres, but not in vector controls. N, IDH1mut inhibitor (AG881 = 1 µmol/L) treatment enhanced PCNA expression in native IDH1mut patient-derived gliomaspheres (HK211, HK252). PCNA protein expression was determined relative to GAPDH protein loading controls. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.
- Open Access
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
IDH1mut production of D-2-HG induces RNA m6A hypermethylation in gliomas. A,IDH1mut patient gliomas manifested RNA m6A hypermethylation, IDH1mut (n = 12) versus IDH1wt (n = 12; P ≤ 0.04). B,IDH1mut gliomaspheres exhibited increased m6A content, IDH1mut (n = 4) versus IDH1wt (n = 7; P ≤ 0.04). In NHA lines, U87 cells, and IDH1wt gliomaspheres, IDH1mut forced expression elevates intracellular D-2-HG content (n = 1; C) and induce m6A enrichment [ANOVA, F(1,27) = 115.0, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector for each cell type] (D). E, Octyl-D-2-HG treatment (0.5 mmol/L) of IDH1wt gliomaspheres increased m6A content compared with PBS treatment controls (n = 6; paired t test; P ≤ 0.01). F, D-2-HG content in HK385, U87, and NHA cells following treatment with IDH1mut inhibitors (C35 = 2 µmol/L; AG881 = 1 µmol/L), quantified using D-2-HG enzymatic assay. G, Effect of IDH1mut inhibitor on m6A content in HK385, U87, and NHA cells with IDH1mut forced expression [ANOVA, IDH1mut inhibitor treatment: F(8,32) = 12.9, P ≤ 0.0001; vector vs. IDH1mut: F(1,32) = 79.22, P ≤ 0.0001; inhibitor and IDH1 status interaction: F(8,32) = 7.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector or between the groups as indicated by horizontal bars]. Pooled data from native IDH1mut gliomaspheres (HK252, HK211) demonstrating a reduction in D-2-HG (one-tailed paired t test; P ≤ 0.04; H) and m6A content (paired t test; P ≤ 0.003; I) following IDH1mut inhibitor AG881 treatment (1.0 µmol/L) in comparison with DMSO control. J, Volcano plot showing the RADAR log2 fold change in m6A expression against −log10 converted P values between IDH1mut and IDH1wt U87, NHA, and gliomasphere cells. Transcript sites with an absolute value log2 fold change of less than 0.5 are excluded (void region in between vertical, dashed red lines). The horizontal, dashed red line indicates the demarcation of RADAR P values <0.01. K, Venn diagram showing the total number of genes fitting TCGA criteria (TCGA P value <1.0 × 10−6; absolute value log2 fold change in RNA expression of 1.0 or greater between IDH1mut and IDH1wt patients) and RADAR criteria (P < 0.01) for all transcripts. Note that the total RADAR gene number is slightly larger here than the totals in J, because this list includes all P < 0.01 transcripts (including those with low magnitude fold changes). L, Supervised hierarchical clustering heat map of intersectional TCGA and RADAR data between U87, NHA, and gliomasphere cell lines that conformed to m6A and RNA expression conventions (i.e., an increase in RADAR m6A expression corresponded to a decrease in TCGA RNA expression). Heat map colors represent sample (columns) natural log converted normalized RADAR m6A values as a difference from the transcript (rows) average across genotype. A transcript of interest, ATF5, is identified. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.
- 22 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
IDH1mut production of D-2-HG induces RNA m6A hypermethylation in gliomas. A,IDH1mut patient gliomas manifested RNA m6A hypermethylation, IDH1mut (n = 12) versus IDH1wt (n = 12; P ≤ 0.04). B,IDH1mut gliomaspheres exhibited increased m6A content, IDH1mut (n = 4) versus IDH1wt (n = 7; P ≤ 0.04). In NHA lines, U87 cells, and IDH1wt gliomaspheres, IDH1mut forced expression elevates intracellular D-2-HG content (n = 1; C) and induce m6A enrichment [ANOVA, F(1,27) = 115.0, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector for each cell type] (D). E, Octyl-D-2-HG treatment (0.5 mmol/L) of IDH1wt gliomaspheres increased m6A content compared with PBS treatment controls (n = 6; paired t test; P ≤ 0.01). F, D-2-HG content in HK385, U87, and NHA cells following treatment with IDH1mut inhibitors (C35 = 2 µmol/L; AG881 = 1 µmol/L), quantified using D-2-HG enzymatic assay. G, Effect of IDH1mut inhibitor on m6A content in HK385, U87, and NHA cells with IDH1mut forced expression [ANOVA, IDH1mut inhibitor treatment: F(8,32) = 12.9, P ≤ 0.0001; vector vs. IDH1mut: F(1,32) = 79.22, P ≤ 0.0001; inhibitor and IDH1 status interaction: F(8,32) = 7.3, P ≤ 0.0001; asterisks indicate post hoc Newman–Keuls comparison with vector or between the groups as indicated by horizontal bars]. Pooled data from native IDH1mut gliomaspheres (HK252, HK211) demonstrating a reduction in D-2-HG (one-tailed paired t test; P ≤ 0.04; H) and m6A content (paired t test; P ≤ 0.003; I) following IDH1mut inhibitor AG881 treatment (1.0 µmol/L) in comparison with DMSO control. J, Volcano plot showing the RADAR log2 fold change in m6A expression against −log10 converted P values between IDH1mut and IDH1wt U87, NHA, and gliomasphere cells. Transcript sites with an absolute value log2 fold change of less than 0.5 are excluded (void region in between vertical, dashed red lines). The horizontal, dashed red line indicates the demarcation of RADAR P values <0.01. K, Venn diagram showing the total number of genes fitting TCGA criteria (TCGA P value <1.0 × 10−6; absolute value log2 fold change in RNA expression of 1.0 or greater between IDH1mut and IDH1wt patients) and RADAR criteria (P < 0.01) for all transcripts. Note that the total RADAR gene number is slightly larger here than the totals in J, because this list includes all P < 0.01 transcripts (including those with low magnitude fold changes). L, Supervised hierarchical clustering heat map of intersectional TCGA and RADAR data between U87, NHA, and gliomasphere cell lines that conformed to m6A and RNA expression conventions (i.e., an increase in RADAR m6A expression corresponded to a decrease in TCGA RNA expression). Heat map colors represent sample (columns) natural log converted normalized RADAR m6A values as a difference from the transcript (rows) average across genotype. A transcript of interest, ATF5, is identified. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; and ****, P ≤ 0.0001 compared with relevant controls. Unless otherwise stated, P values indicate unpaired Student t test comparisons with the control, or between two groups as indicated by the horizontal line.